STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio...
Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) )
Also on site :
- Julia Fox's Net Worth in 2025 Proves She's an It Girl
- Israel strikes Syria again, claims to have killed alleged Hamas member
- Plane crashes at Tennessee Airport: Injuries recorded